

Urgent/ By Speed Post/ Email

फा. सं. 37001/2020/Div. III/NPPA

Government of India/ भारत सरकार

Ministry of Chemicals & Fertilizers/ रसायन एवं उर्वरक मंत्रालय

Department of Pharmaceuticals/ औषध विभाग

National Pharmaceutical Pricing Authority/ राष्ट्रीय औषध मूल्य निर्धारण प्राधिकरण

3rd/5th Floor

YMCA Culture Centre Building

वाई.एम.सी.ए. सांस्कृतिक केन्द्र बिल्डिंग

1, Jai Singh Road, N. Delhi-110001

1, जय सिंह रोड, नई दिल्ली-110001

Date/ दिनांक: 03.07.2020

Subject: Availability of Drug Methyl Prednisolone (IV), Enoxaparin and Dexamethasone-reg.

Sir,


The undersigned is directed to invite a reference to MoHFW letters no. 18-03/2020-DC/COVID-19 dated 29th June 2020, letter no-X.11035/206/2020-DR dated 24.06.2020 and letter No. X.11035/206/2020-DR dated 27.06.2020, regarding the requirement and availability of above mentioned drugs across the country since they are part of the clinical treatment protocol of COVID-19. DGHS has informed that the requirement is likely to be as follows:

S.No	Drug Name	Quantity	Period (Up to)
1	Methyl Prednisolone	138710 vials	31.07.2020
2	Heparin (Enoxaparin)	3015442 vials (40mg) 1407206 vials (60mg)	31.07.2020
3	Dexamethasone	33 lakh tablet (~6mg)	15.08.2020

2. In view of above the Manufacturers of above mentioned drugs are directed to:

- Ensure the production of above mentioned drugs in adequate quantity (Quantity indicated above) and to take proactive steps to maintain adequate stock and ensure supply across the country.
- Make available adequate stocks across country and whenever and wherever short supply is reported.
- Immediately intimate details regarding:

- Production/Sale of above mentioned drugs during the last 2 years (FY. 2018-19, 2019-20)
- Stock lying with your Company as on date
- Production schedule for next six months
- Details of suppliers from whom you are sourcing API for above mentioned drugs and problems, if any, being faced in such sourcing
- Details of procurement orders placed by state governments
- Additional details may also be provided in the format enclosed

भवदीय,

(मंजेश पोरवाल)
उप-निदेशक (एम एंड ई)

To,

The Managing Director/CEO,


All Manufacturers of Drugs Methyl Prednisolone (IV), Enoxaparin and Dexamethsone as per list enclosed (For immediate compliance)

Copy for necessary action to:

All the State Drugs Controllers (SDCs) with the request to issue necessary direction to the manufacturers of above said medicine to ensure the availability of these medicines across the country.

Copy for Information and necessary action to:

1. Sh. R.G. Singh, Under Secretary, MoHFW, Nirman Bhawan, New Delhi
2. DGHS, MoHFW, Nirman Bhawan, New Delhi.
3. DCGI, CDSCO, FDA Bhawan, New Delhi



Major Manufacturer of Mythyl Prednisolone

Sr. No.	COMPANY	Market Share %
1	PFIZER LTD	43.41%
2	SUN PHARMA LABORATORIES LTD.	28.92%
3	NEON LABORATORIES LTD	8.44%
4	INTAS PHARMACEUTICALS LTD	7.67%
5	ZYDUS CADILA	5.85%
6	Others	5.71%

Major Manufacturer of Enoxaparin Inj.

Sr. No.	COMPANY	Market Share %
1	BHARAT SERUMS & VACCINES LTD	18.89%
2	SANOFI INDIA LTD.	18.07%
3	EMCURE PHARMACEUTICALS LTD	13.41%
4	CIPLA LTD.	8.49%
5	ABBOTT HEALTHCARE PVT. LTD	6.75%
6	Others	34.40%

Major Manufacturer of Dexamethsone

Sr. No.	COMPANY	Market Share %
1	Wochardt LTD.	15.85%
2	CADILA PHARMACEUTICALS LTD	1.53%
3	ZYDUS CADILA	80.20%